CO220 Real-World Effectiveness and Safety in a Phase 4 Study of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis

Abstract

Authors

N. Bhatia J.G. Vasquez B. Schenkel S.J. Rozzo J. Heim

Full Text Cite This Article
Back to Volume 26, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×